PGC-1α role in rescuing ferroptosis in cerebral ischemia/reperfusion injury through promoting mitochondrial biogenesis and UCP2 expression

》》文章原文链接：PGC-1α role in rescuing ferroptosis in cerebral ischemia/reperfusion injury through promoting mitochondrial biogenesis and UCP2 expression

》》Journal：BBA - Molecular Basis of Disease

》》相关产品：Liproxstatin-1 (SJ-MX0055)

》》产品引用描述：

》》Abstract：

Cerebral ischemia/reperfusion injury (CIRI) is a critical factor leading to adverse outcomes in acute ischemic stroke with reperfusion therapy. The occurrence of CIRI involves several cell death pathways, such as ferroptosis. Peroxisome proliferator-activated receptor-γ coactivator 1α (PGC-1α) a vital role in mitochondrial biogenesis and induces several crucial reactive oxygen species (ROS) detoxifying enzymes. Nonetheless, the role of activated PGC-1α in CIRI is still unclear. In this research, we utilized a PGC-1α agonist (ZLN005) in both in vitro and in vivo models of CIRI and found that ZLN005 ameliorates neurologic deficits, reduces infarct volume, and inhibits neuronal ferroptosis in CIRI. Furthermore, CIRI led to a decrease in neuronal mitochondrial quantity and downregulation of uncoupling protein 2 (UCP2) expression. Treatment with ZLN005 activated PGC-1α, promoted neuronal mitochondrial biogenesis, and upregulated UCP2 expression, thereby reducing mitochondrial oxidative stress. The application of the mitochondria-targeted antioxidant Mito-TEMPO inhibited ferroptosis, while UCP2 silencing induced mitochondrial oxidative stress and weakened ZLN005 inhibitory effect of ferroptosis, confirming the dependency of ferroptosis on mitochondrial oxidative stress in CIRI. According to these findings, targeting PGC-1α may offer an effective therapeutic strategy for CIRI by regulating mitochondrial homeostasis and protecting neurons from ferroptotic damage.

》》部分实验数据展示：

Fig. 2. Liproxstatin-1 (Lip-1) inhibits ferroptosis in Oxygen-Glucose Deprivation/Reoxygenation (OGD/R). (D) Flow cytometry analysis of lipid ROS levels in HT22 cells under OGD/R and Lip-1 treatment using the C11-BODIPY fluorescent probe. ***P < 0.001, **P < 0.01. (E) MDA levels in HT22 cells under OGD/R and Lip-1 treatment. **P < 0.01. (F) Laser confocal images of lipid ROS levels in HT22 cells (scale bar, 20 μm). (G) Flow cytometry analysis of mitochondrial membrane potential (ΔΨm) in HT22 cells using JC-1 fluorescence probe under OGD/R and Lip-1 treatments. ***P < 0.001. (H) ATP levels in HT22 cells under OGD/R and Lip-1 treatment.